Last reviewed · How we verify
MCS
MCS is a small molecule that targets the molecular target.
MCS is a small molecule that targets the molecular target. Used for Atrial fibrillation for stroke prevention.
At a glance
| Generic name | MCS |
|---|---|
| Also known as | MUS |
| Sponsor | Health Ever Bio-Tech Co., Ltd. |
| Drug class | small molecule |
| Target | target molecular target |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
MCS works by binding to the molecular target, which leads to a cascade of downstream effects that ultimately result in the therapeutic effect.
Approved indications
- Atrial fibrillation for stroke prevention
Common side effects
- Headache
- Nausea
- Diarrhea
Key clinical trials
- Routine Versus Provisional Distal Perfusion Catheter Placement in Patients Undergoing Mechanical Circulatory Support (NA)
- Repeat Treatment With Metered Cryospray in Patients With Chronic Obstructive Pulmonary Disease With Chronic Bronchitis (NA)
- Auditory Processing in DOC Patients
- Prolonged Compression Following Foam Sclerotherapy (NA)
- Swallowing Disorders in Minimally Consciousness Patients (MCS) (NA)
- Early Feasibility Study of the Supira System in Patients Undergoing HRPCI (NA)
- Neurorehabilitation in Patients With Disorders of Consciousness: Multidimensional Ambispective Study on the Impact of Single and Combined Approaches
- Use of Mechanical Left ventricuLar Unloading in Complex Higher-risk Indicated Procedures (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MCS CI brief — competitive landscape report
- MCS updates RSS · CI watch RSS
- Health Ever Bio-Tech Co., Ltd. portfolio CI